Board Update

Clinigen Group plc (AIM: CLIN) (‘Clinigen’ or the ‘Company’ or the ‘Group’), the global pharmaceutical Services and Products company, announces that Elmar Schnee, Non-Executive Director and Chairman designate, will become Chairman with immediate effect. Simultaneously, and following the announcement on 13 July, Peter Allen will step down as Chairman.

Shaun Chilton, Chief Executive Officer of Clinigen, said: “I would like to thank Peter on behalf of the Board, and personally, for his valued leadership and contributions since Clinigen’s IPO in 2012. I have enjoyed working with Elmar to date and look forward to working more closely with him as we continue to grow the Company and deliver value.”

Elmar Schnee, Chairman, said: “Clinigen has built a strong global business that is uniquely well-positioned to provide an end-to-end service to pharmaceutical clients. I look forward to continuing to work with the Board and management as we build upon the Company’s successes to date and realise the full potential of its lifecycle platform.”

Peter Allen, outgoing Chairman, added: “I am proud to have spent nine years as Chairman of Clinigen. During that time the Company has grown and developed into a global leader in providing global access to medicines, delivering significant value to patients, customers and shareholders. I have every confidence in Clinigen’s continued success.”

Following today’s announcement, the members of Clinigen’s Board of Directors are as follows:

Elmar Schnee, Independent Non-Executive Director and Chairman
Shaun Chilton, Chief Executive Officer
Ian Johnson, Senior Independent Director
Anne Hyland, Independent Non-Executive Director
Alan Boyd, Non-Executive Director
Ian Nicholson, Independent Non-Executive Director
Sharon Curran, Independent Non-Executive Director

Elmar Schnee’s biography

Elmar Schnee brings a wealth of experience from the international pharmaceutical industry, having held senior leadership and Board positions at a number of pharmaceutical products and services companies. Elmar most recently served on the Board of Jazz Pharmaceuticals, since 2014. He serves as a Non-Executive Director on a number of other pharmaceutical company Boards, including Santhera AG and Calliditas AB, alongside several other private biopharma companies. Prior to this his career spanned a range of senior roles at companies including Merck KGaA, including as General Partner and a member of the executive Board, and at Merck Serono as CEO. He has also held senior management positions at UCB and Sanofi. He holds both a bachelor's degree in marketing and a master's degree in marketing and general management from the Swiss Institute of Business Administration in Zurich. In addition to Santhera and Calliditas, Elmar Schnee also serves as a director of Genkyotex SA, Moleac Pte, Moleac RX Pte, Noorik AG, Damian Pharma AG, Kuste Biopharma, Mindmaze, Genpharm, GenKyoTex Suisse SA, ProCom RX Holding SA and MyDIO SA.

The Group confirms that further to Clinigen’s announcement on 3 August 2021, there are no further disclosures to be made on Elmar Schnee in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules

Upcoming Full Year results

The Group will publish its final results for the year ended 30 June 2021 on Thursday 16 September 2021 and financial guidance remains unchanged.

For more information, please contact:

Clinigen Group plc
Shaun Chilton, Chief Executive Officer
Rob Fox, VP Investor Relations and Corporate Development
+44 (0) 1283 495010
investors@clinigengroup.com

Numis Securities Limited - Nominated Adviser & Joint Broker
James Black / Garry Levin / Freddie Barnfield
Tel: +44 (0) 20 7260 1000
Clinigen@Numis.com

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0) 20 7653 4000

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Hodgson
Tel: +44 (0) 20 3709 5700
Clinigen@consilium-comms.com

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit http://www.clinigen.com